Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Epistemonikos ID: e6ba73453c40c628bab8f0fb77c3b1904ced8950
First added on: May 10, 2024